File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response

TitleGenetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response
Authors
KeywordsAge-related macular degeneration
Issue Date2016
Citation
Ophthalmologica, 2016 How to Cite?
Abstract© 2016 S. Karger AG, BaselObjective: To evaluate the pharmacogenetic relationship between CFH haplotypes and single nucleotide polymorphisms (SNPs) with response to ranibizumab treatment for neovascular age-related macular degeneration (nAMD). Patients and Methods: This was a prospective cohort study involving 70 treatment-naive nAMD patients. Patients were genotyped for CFH haplotypes and SNPs in the C3, ARMS2, and mtDNA genes. Visual acuity and central macular thickness were assessed at baseline and during 6 monthly follow-up visits. Multivariate logistic regression was used to determine the association between genotypes and a gain of ≥15 letters at the 6-month endpoint after adjusting for potential confounders. Results:CFH haplotypes were associated with a gain of ≥15 letters at the 6-month endpoint (p = 0.046). Patients expressing protective haplotypes were more likely to achieve a gain of ≥15 letters relative to the greatly increased risk haplotypes [OR 6.58 (95% CI: 1.37, 31.59)]. Conclusion:CFH is implicated in nAMD patient treatment response to ranibizumab.
Persistent Identifierhttp://hdl.handle.net/10722/228255
ISSN
2015 Impact Factor: 1.515
2015 SCImago Journal Rankings: 1.033

 

DC FieldValueLanguage
dc.contributor.authorChaudhary, Varun-
dc.contributor.authorBrent, Michael-
dc.contributor.authorLam, Wai Ching-
dc.contributor.authorDevenyi, Robert-
dc.contributor.authorTeichman, Joshua-
dc.contributor.authorMak, Michael-
dc.contributor.authorBarbosa, Joshua-
dc.contributor.authorKaur, Harneel-
dc.contributor.authorCarter, Ronald-
dc.contributor.authorFarrokhyar, Forough-
dc.date.accessioned2016-08-01T06:45:35Z-
dc.date.available2016-08-01T06:45:35Z-
dc.date.issued2016-
dc.identifier.citationOphthalmologica, 2016-
dc.identifier.issn0030-3755-
dc.identifier.urihttp://hdl.handle.net/10722/228255-
dc.description.abstract© 2016 S. Karger AG, BaselObjective: To evaluate the pharmacogenetic relationship between CFH haplotypes and single nucleotide polymorphisms (SNPs) with response to ranibizumab treatment for neovascular age-related macular degeneration (nAMD). Patients and Methods: This was a prospective cohort study involving 70 treatment-naive nAMD patients. Patients were genotyped for CFH haplotypes and SNPs in the C3, ARMS2, and mtDNA genes. Visual acuity and central macular thickness were assessed at baseline and during 6 monthly follow-up visits. Multivariate logistic regression was used to determine the association between genotypes and a gain of ≥15 letters at the 6-month endpoint after adjusting for potential confounders. Results:CFH haplotypes were associated with a gain of ≥15 letters at the 6-month endpoint (p = 0.046). Patients expressing protective haplotypes were more likely to achieve a gain of ≥15 letters relative to the greatly increased risk haplotypes [OR 6.58 (95% CI: 1.37, 31.59)]. Conclusion:CFH is implicated in nAMD patient treatment response to ranibizumab.-
dc.languageeng-
dc.relation.ispartofOphthalmologica-
dc.subjectAge-related macular degeneration-
dc.titleGenetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1159/000446819-
dc.identifier.scopuseid_2-s2.0-84978058374-
dc.identifier.spagenull-
dc.identifier.epagenull-
dc.identifier.eissn1423-0267-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats